ATE494306T1 - Humanisierte anti-cd100-antikörper - Google Patents
Humanisierte anti-cd100-antikörperInfo
- Publication number
- ATE494306T1 ATE494306T1 AT08729737T AT08729737T ATE494306T1 AT E494306 T1 ATE494306 T1 AT E494306T1 AT 08729737 T AT08729737 T AT 08729737T AT 08729737 T AT08729737 T AT 08729737T AT E494306 T1 ATE494306 T1 AT E494306T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- compositions
- antigen
- antibody
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90153007P | 2007-02-14 | 2007-02-14 | |
| PCT/US2008/053816 WO2008100995A1 (en) | 2007-02-14 | 2008-02-13 | Humanized anti-cd100 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494306T1 true ATE494306T1 (de) | 2011-01-15 |
Family
ID=39535347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08729737T ATE494306T1 (de) | 2007-02-14 | 2008-02-13 | Humanisierte anti-cd100-antikörper |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7919594B2 (de) |
| EP (1) | EP2069404B1 (de) |
| AT (1) | ATE494306T1 (de) |
| DE (1) | DE602008004296D1 (de) |
| WO (1) | WO2008100995A1 (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2568436T3 (es) * | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
| ES2429407T3 (es) * | 2006-06-08 | 2013-11-14 | Chugai Seiyaku Kabushiki Kaisha | Agente preventivo o remedio para enfermedades inflamatorias |
| SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
| EP3689912A1 (de) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr |
| MX2010006097A (es) * | 2007-12-05 | 2010-08-04 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para tratar el prurito. |
| RU2531521C2 (ru) * | 2007-12-05 | 2014-10-20 | Чугаи Сейяку Кабусики Кайся | Антитело против nr10 и его применение |
| EP4238993A3 (de) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigenbindendes molekül zur wiederholten bindung an zwei oder mehr antigenmoleküle |
| CA2722466A1 (en) * | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CA2725666A1 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| NZ594514A (en) * | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
| MX2011011718A (es) * | 2009-05-08 | 2012-01-27 | Vaccinex Inc | Anticuerpos anti-cd100 y metodos para su uso. |
| WO2010151341A1 (en) * | 2009-06-24 | 2010-12-29 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| IN2012DN02737A (de) * | 2009-09-01 | 2015-09-11 | Abbott Lab | |
| KR20140015139A (ko) * | 2009-10-15 | 2014-02-06 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011140249A2 (en) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CN103945868B (zh) * | 2011-05-13 | 2016-10-26 | 国立大学法人东京医科齿科大学 | 骨生成促进剂 |
| CN110105452A (zh) * | 2011-10-11 | 2019-08-09 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| ES2837826T3 (es) | 2012-05-30 | 2021-07-01 | Univ Rowan | Terapia metabólica para el estrés oxidativo en el cerebro a través del catabolismo neuronal direccionado del ácido N-acetil-aspártico |
| RU2718751C2 (ru) | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r) |
| AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| DK3013350T3 (da) * | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10975153B2 (en) | 2014-06-23 | 2021-04-13 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| SG11201702723VA (en) | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| KR20170096187A (ko) | 2014-12-22 | 2017-08-23 | 파이브 프라임 테라퓨틱스, 인크. | Pvns를 치료하기 위한 항-csf1r 항체 |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP4059516A1 (de) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integrale membranproteinanzeige auf extrazellulären umhüllten virionen des pockenvirus |
| CN109563143A (zh) | 2016-08-02 | 2019-04-02 | 瓦西尼斯公司 | 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法 |
| DK3600419T5 (en) * | 2017-03-20 | 2023-11-13 | Vaccinex Inc | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
| AU2018261947A1 (en) | 2017-05-05 | 2019-11-07 | Vaccinex, Inc. | Human anti-semaphorin 4D antibody |
| WO2019055537A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | ANTI-CSF1R AND ANTI-PD -1 ANTIBODY POLYTHERAPY FOR PANCREATIC CANCER |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| JP7362767B2 (ja) | 2019-03-28 | 2023-10-17 | バクシネックス インコーポレーティッド | がん療法で使用するためのセマフォリン－４ｄアンタゴニスト |
| EP3986446A1 (de) | 2019-06-21 | 2022-04-27 | Vaccinex, Inc. | Kombinationstherapie mit semaphorin-4d-blockade (sema4d) und dc1-therapie |
| EP4007774A1 (de) | 2019-08-01 | 2022-06-08 | Vaccinex, Inc. | Kombinierte hemmung von semaphorin-4d und tgfb und zusammensetzungen dafür |
| TW202128222A (zh) | 2019-11-20 | 2021-08-01 | 日商中外製藥股份有限公司 | 含有抗體之製劑 |
| CA3181833A1 (en) | 2020-06-25 | 2021-12-30 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for the treatment of rett syndrome |
| EP4251748A1 (de) * | 2020-11-30 | 2023-10-04 | Merck Sharp & Dohme LLC | Arginase-1-bindemittel zur hemmung der arginase-1-aktivität |
| WO2023048726A1 (en) | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN117866091A (zh) * | 2022-10-12 | 2024-04-12 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
| WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| EP1442749A1 (de) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verwendung von einem Antikörper gegen CD100 für die Diagnose und die Behandlung von einer entzündlichen Krankheit des Zentralnervensystems |
| CA2603780A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Sema4d in cancer diagnosis, detection and treatment |
-
2008
- 2008-02-13 DE DE602008004296T patent/DE602008004296D1/de active Active
- 2008-02-13 EP EP08729737A patent/EP2069404B1/de active Active
- 2008-02-13 US US12/030,356 patent/US7919594B2/en active Active
- 2008-02-13 WO PCT/US2008/053816 patent/WO2008100995A1/en active Application Filing
- 2008-02-13 AT AT08729737T patent/ATE494306T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602008004296D1 (de) | 2011-02-17 |
| WO2008100995A1 (en) | 2008-08-21 |
| EP2069404A1 (de) | 2009-06-17 |
| EP2069404B1 (de) | 2011-01-05 |
| US20080219971A1 (en) | 2008-09-11 |
| US7919594B2 (en) | 2011-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE494306T1 (de) | Humanisierte anti-cd100-antikörper | |
| MX2009003838A (es) | Anticuerpos anti-cd20 y metodos de uso. | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| HUS2200044I1 (hu) | Humanizált anti-CD19 ellenanyagok és használatuk daganatokban, transzplantációknál és autoimmun betegségekben | |
| CY1122270T1 (el) | Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων | |
| JP2013519375A5 (de) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| EA200901533A1 (ru) | Антитела il-6 и их применение | |
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| UA95478C2 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| BRPI0606547A2 (pt) | anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado | |
| MY157173A (en) | Modified humanised anti-interleukin-18 | |
| EP1996716A4 (de) | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting | |
| MX343879B (es) | Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados. | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2013227339A5 (de) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| EA020130B9 (ru) | Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата | |
| AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| JP2020502271A5 (de) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| NZ598670A (en) | Antibodies against glucagon receptor and their use | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |